BRAF and melanoma: Recent studies have tested adjuvant systemic TT and IT for resected stage III/IV melanoma, with the aims of reducing melanoma recurrence and prolonging patient survival.6,7 Whilst TT is reserved for patients with BRAF V600 mutant melanoma, IT may be used in patients irrespective of their BRAF status.